Shares for Thousand Oaks-based biotech giant Amgen were on the rise July 13 after it resubmitted an application to the U.S. Food and Drug Administration for its osteoporosis treatment Evenity. The new Biologics License Application includes data from two new Phase 3 studies including more than more than 4,000 women and 245 men. Evenity aims…
This article is only available to Business Times subscribers
Subscribers: LOG IN or REGISTER for complete digital access.
Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists.
